Bristol Myers Squibb
SOTYKTU deucravacitinib 6 mg Tablet 28
61/100
SUPPIE SCORE
85/100
EFFICACY
Low
SAFETY
84/100
CLEANLINESS
What Does SOTYKTU deucravacitinib 6 mg Tablet 28 Do?
SOTYKTU (deucravacitinib 6 mg) is a prescription TYK2 inhibitor with strong evidence from phase 3 trials for moderate-to-severe plaque psoriasis clearance.
What is the recommended way to store SOTYKTU safely around children?
Are there specific lab tests needed while taking deucravacitinib 6 mg daily?
What infections or conditions require caution before starting this prescription medicine?
Chat with Suppie
What Are the Benefits of SOTYKTU deucravacitinib 6 mg Tablet 28?
Based on proven scientific research
Plaque Psoriasis ClearanceStrong
Skin Symptom ImprovementModerate
Quality of Life EnhancementModerate
Good For:
What Are the Side Effects of Bristol Myers Squibb SOTYKTU deucravacitinib 6 mg Tablet 28?
Always consult your health practitioner if in doubt.
RiskHigh Risk
Overview
•Deucravacitinib 6 mg daily is associated with increased risk of infections including upper respiratory tract infections, nasopharyngitis, and herpes zoster reactivation.
•Clinical trials showed elevated creatine phosphokinase (CPK) levels that may lead to rhabdomyolysis; discontinue if markedly elevated or myopathy suspected.
•Periodic monitoring of serum triglycerides, liver enzymes, and blood counts is recommended due to observed elevations.
•Malignancies including non-melanoma skin cancer and lymphomas were reported; risk is higher in psoriasis patients.
•Not recommended in severe hepatic impairment; evaluate for latent TB before starting and avoid live vaccines during treatment.
Potential Side Effects
Negative Interactions
Allergens
Lactose
Inactive Ingredients
Lactose
Medium RiskMicrocrystalline cellulose
Low RiskCroscarmellose sodium
Low RiskSilicon dioxide
Low RiskMagnesium stearate
Low RiskHypromellose acetate succinate
Low RiskOpadry ii pink film coating
Low RiskWhat Are the Ingredients in Bristol Myers Squibb SOTYKTU deucravacitinib 6 mg Tablet 28?
deucravacitinib
6 mg
Lactose
Microcrystalline cellulose
Croscarmellose sodium
Silicon dioxide
Magnesium stearate
Hypromellose acetate succinate
Opadry II pink film coating
Dosage & Bioavailability
How the active doses and forms in SOTYKTU deucravacitinib 6 mg Tablet 28 compare to the research.
•Deucravacitinib is listed at 6 mg per serving; without a source-specific reference range, dose adequacy cannot be graded.
•Deucravacitinib has no distinct chemical or delivery form stated, so no product-specific absorption advantage can be established.
Sources & References
How to keep prescription medication out of reach of children
Information from cardinalbagsupplies.com
Keeping prescription drugs from children
Information from toomuchtolose.org
Auspar sotyktu 230830 pi.pdf
Information from www.tga.gov.au
376290
Information from www.tga.gov.au
How to keep prescription medication out of reach of children
Information from cardinalbagsupplies.com
Keeping prescription drugs from children
Information from toomuchtolose.org
Frequently Asked Questions
Common questions about Bristol Myers Squibb SOTYKTU deucravacitinib 6 mg Tablet 28